This document is an excerpt from the EUR-Lex website
Document 62017TB0733
Case T-733/17 R: Order of the President of the General Court of 23 November 2018 — GMPO v Commission (Interim relief — Medicinal products for human use — Active substance trientine tetrahydrochloride — Commission decision not to classify the medicinal product Cuprior-trientine as an orphan medicinal product — Regulation (EC) No 141/2000 — Application for suspension of operation of a measure — Lack of urgency)
Case T-733/17 R: Order of the President of the General Court of 23 November 2018 — GMPO v Commission (Interim relief — Medicinal products for human use — Active substance trientine tetrahydrochloride — Commission decision not to classify the medicinal product Cuprior-trientine as an orphan medicinal product — Regulation (EC) No 141/2000 — Application for suspension of operation of a measure — Lack of urgency)
Case T-733/17 R: Order of the President of the General Court of 23 November 2018 — GMPO v Commission (Interim relief — Medicinal products for human use — Active substance trientine tetrahydrochloride — Commission decision not to classify the medicinal product Cuprior-trientine as an orphan medicinal product — Regulation (EC) No 141/2000 — Application for suspension of operation of a measure — Lack of urgency)
IO C 44, 4.2.2019, pp. 65–66
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
4.2.2019 |
EN |
Official Journal of the European Union |
C 44/65 |
Order of the President of the General Court of 23 November 2018 — GMPO v Commission
(Case T-733/17 R)
((Interim relief - Medicinal products for human use - Active substance trientine tetrahydrochloride - Commission decision not to classify the medicinal product Cuprior-trientine as an orphan medicinal product - Regulation (EC) No 141/2000 - Application for suspension of operation of a measure - Lack of urgency))
(2019/C 44/85)
Language of the case: English
Parties
Applicant: GMP-Orphan (GMPO) (Paris, France) (represented by: M. Demetriou QC, E. Mackenzie, Barrister, L. Tsang and J. Mulryne, Solicitors)
Defendant: European Commission (represented by: K. Petersen and A. Sipos, acting as Agents)
Re:
Application under Articles 278 and 279 TFEU for suspension of operation of Article 5 of Commission Implementing Decision C(2017) 6102 final of 5 September 2017 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1) for ‘Cuprior-trientine’, a medicinal product for human use.
Operative part of the order
|
1. |
The application for interim measures is dismissed. |
|
2. |
The costs are reserved. |